SG Americas Securities LLC Buys 23,757 Shares of Xencor, Inc. (NASDAQ:XNCR)

SG Americas Securities LLC raised its stake in Xencor, Inc. (NASDAQ:XNCR) by 292.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 31,887 shares of the biopharmaceutical company’s stock after acquiring an additional 23,757 shares during the period. SG Americas Securities LLC’s holdings in Xencor were worth $641,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Primecap Management Co. CA increased its holdings in Xencor by 0.3% in the 2nd quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock valued at $172,570,000 after acquiring an additional 25,495 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Xencor by 3.6% in the 1st quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock worth $155,154,000 after buying an additional 243,793 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Xencor by 9.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock valued at $84,530,000 after purchasing an additional 335,881 shares during the last quarter. Logos Global Management LP grew its holdings in Xencor by 130.8% during the 2nd quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $28,395,000 after purchasing an additional 850,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Xencor by 6.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock valued at $27,628,000 after purchasing an additional 87,979 shares during the last quarter.

Xencor Stock Down 1.2 %

NASDAQ:XNCR opened at $21.03 on Tuesday. The firm has a market capitalization of $1.30 billion, a P/E ratio of -9.60 and a beta of 0.67. Xencor, Inc. has a 1-year low of $15.31 and a 1-year high of $26.84. The company’s fifty day moving average price is $18.53 and its 200-day moving average price is $20.12. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.92 and a quick ratio of 6.92.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). Xencor had a negative return on equity of 28.23% and a negative net margin of 132.74%. The firm had revenue of $16.96 million for the quarter, compared to analysts’ expectations of $21.13 million. During the same period last year, the company posted ($0.37) earnings per share. The business’s quarterly revenue was down 62.7% on a year-over-year basis. As a group, equities research analysts anticipate that Xencor, Inc. will post -4.15 EPS for the current year.

Analysts Set New Price Targets

XNCR has been the subject of several research reports. BMO Capital Markets reissued an “outperform” rating and issued a $32.00 price objective on shares of Xencor in a research report on Tuesday, August 6th. Royal Bank of Canada boosted their price objective on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. Wedbush reiterated an “outperform” rating and set a $34.00 price objective on shares of Xencor in a research note on Monday, September 9th. Finally, JPMorgan Chase & Co. cut their price target on shares of Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.78.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.